The U.S. Food and Drug Administration on January 15, 2025, announced its decision to ban Red Dye No. 3 also referred to as Erythrosine.

It is a synthetic food dye that gives certain foods and drinks a bright, cherry-red color, and is found in certain candy, cakes and cupcakes, cookies, frozen desserts, and frostings and icings, and ingested drugs. Like other color additives, its uses must be approved by the FDA, and it is used in small amounts. The FDA requires manufacturers to list FD&C Red No. 3 in the statement of ingredients when added to food.

Besides, it does not offer any nutritional value and poses potential risks. It has been linked to cancer in animals. American health officials have barred the use of artificial food colouring Red No. 3, decades after the dye was removed from cosmetics.

However, its history has been clouded by controversy, due to its link to cancer in animal studies—a step long overdue. Red Dye No. 3 is already banned or restricted in many countries, including Australia and Japan. California announced a ban of the dye in food throughout the state in 2023, and other states began introducing legislation to restrict its use, according to the Center for Science in the Public Interest.

Regulatory Information

The FDA will no longer allow for the use of FD&C Red No. 3 in food and ingested drugs Following this ban, manufacturers who use FD&C Red No. 3 in food and ingested drugs will have until January 15, 2027 or January 18, 2028, respectively, to reformulate their products.

Consumers could see FD&C Red No. 3 as an ingredient in a food or drug product on the market past the effective date in the order if that product was manufactured before the effective date.

The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats. While the FDA cites no direct evidence of Red 3’s carcinogenic effect in people, it acknowledges that animal studies provide sufficient basis for regulatory action.

The US agency said its decision was based on the federal law called the Delaney Clause, which prohibits the use of any additive that causes cancer in humans or animals in food.

Further the agency also emphasized  that harmonizing global standards on regulating and evaluating synthetic dyes is essential to protect consumer health.

Reference:

FD&C Red No. 3 | FDA

READ MORE
Exim rebrands as ExSyn: We celebrate our 30-year heritage with a new brand and website that bring alive our values and purpose
News · 27/03/2021

Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.

In focus: 5-Methyl-3-vinyl-2-oxazolidinone
Products in focus · 14/10/2025

5-Methyl-3-vinyl-2-oxazolidinone (V-MOX) is a highly reactive monomer valued for its low viscosity, mild odor, and excellent reactivity. It is widely used as a reactive diluent in UV-curable inks and coatings, where it enhances adhesion, produces brighter colors, and improves safety compared to conventional diluents. In addition, V-MOX serves as a key building block in the synthesis of kinetic hydrate inhibitor (KHI) polymers, which are applied in oil and gas production to prevent hydrate blockages in pipelines.

In focus: Zinc Ricinoleate
Products in focus · 07/10/2025

Zinc ricinoleate is the zinc salt of ricinoleic acid, a hydroxylated fatty acid derived mainly from castor oil (Ricinus communis). It appears as a white to slightly yellowish powder, waxy solid, or paste, depending on formulation. Its most valuable property is its ability to trap and absorb odor molecules such as amines, sulfides, and short-chain fatty acids, making it an essential ingredient in deodorant and odor-control products.

Australian Study Reveals Significant Cost Savings and Market Impact From Biosimilars
News · 01/10/2025

The economic impact of biosimilars on the Australian health care system is now clearer, with data revealing their role in reducing market expenditure and driving price competition.